All News
Filter News
Found 11,897 articles
-
NanoSyrinx appoints Anthony Johnson as Non-Executive Director
11/10/2023
NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.
-
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
11/9/2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent operational highlights.
-
Pediatric Drugs Market Size to Garner Around USD 363.86 Billion by 2032
11/8/2023
The global pediatric drugs market size is predicted to garner around USD 363.86 billion by 2032 and is expanding at a CAGR of 12.2% over the forecast period 2023 to 2032.
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
11/7/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the third quarter ended September 30, 2023.
-
Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
11/6/2023
Avalyn Pharma Inc. announced four leadership appointments across the organization, including lung disease drug development expert Craig Conoscenti, M.D., FCCP, ATSF, who will serve as senior vice president, clinical development.
-
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
11/6/2023
NeuroBo Pharmaceuticals, Inc. today announced the appointment of James P. Tursi , M.D., a pharmaceutical industry veteran, to its Board of Directors, effective November 1, 2023.
-
Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program
11/2/2023
Prokarium announces that the U.S. Food and Drug Administration has granted the company's Investigational New Drug application for their immunotherapy ZH9.
-
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/2/2023
Moderna, Inc. reported financial results and provided business updates for the third quarter of 2023.
-
The British biopharma company reported 10% sales growth in the third quarter, driven mainly by robust sales of its respiratory syncytial virus shot Arexvy and shingles vaccine Shingrix.
-
The British biopharma and Arrowhead Pharmaceuticals have reached an agreement with J&J’s Janssen to transfer worldwide rights to develop and commercialize JNJ-3989 to GSK.
-
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
10/30/2023
23andMe Holding Co. announced a new, non-exclusive data license with GSK plc which extends their collaboration and enables GSK to conduct drug target discovery and other research using the 23andMe database, the world’s largest recontactable resource of genetic and phenotypic information from consented participants.
-
The company’s respiratory syncytial virus vaccine Arexvy can elicit similar levels of immune protection in adults aged 50 to 59 as in its approved population, finds results from a late-stage study.
-
Onconova Expands Leadership Team with Two Key Appointments
10/24/2023
Onconova Therapeutics, Inc. announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer, and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development.
-
Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone
10/22/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 MAGNITUDE study.
-
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
10/19/2023
Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA at Independent Non-Executive Director.
-
Lao PDR Reaches Incredible Milestone in Mitigating Neglected Tropical Diseases with Elimination of Lymphatic Filariasis
10/18/2023
RTI International, a nonprofit research institute and leading international development organization, joins the Lao People's Democratic Republic (Lao PDR), World Health Organization, and the U.S. Agency for International Development (USAID) in celebrating Lao PDR's achievement of eliminating lymphatic filariasis as a public health problem.
-
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
10/16/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that nine oral presentations from the Company's robust solid tumor portfolio and pipeline, with three highlighted in Presidential Symposium sessions, will be featured at the European Society for Medical Oncology (ESMO) 2023 Congress.
-
Clinical Trial Finds Live Vaccinations Safe for Liver, Kidney Transplant Recipients
10/16/2023
Live vaccinations provided to children who previously received liver or kidney transplants were found to be safe and prompted an immune response to guard against several life-threatening conditions, according to a new study published Oct. 12, 2023, in JAMA Network Open.
-
SaponiQx Advances Vaccine Development With the Availability of cGMP QS-21 From Its Proprietary Cultured Plant Cell Source
10/10/2023
Agenus subsidiary, SaponiQx, a leader in saponin-based adjuvant discovery and production, announces a pivotal advancement in vaccine research and production with the availability of cGMP (current good manufacturing practice) STIMULON™ cultured plant cell (cpc) QS-21. STIMULON cpcQS-21 is a sustainable and cost-efficient alternative to conventionally extracted QS-21 from bark extract, used in high-performance vaccines such as SHINGRIX and AREXVY.
-
The pharmaceutical giant aims to hire another 50 people by the end of this year to work on a new platform dedicated to harnessing data and AI insights in drug discovery.